Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,801 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06453902RecruitingPhase 2
Testing TGRX-678 for advanced CML after prior treatments
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Beijing, Beijing MunicipalityAges 18 years+ - NCT06456359RecruitingPhase 2
Pasireotide maintenance for synovial sarcoma and DSRCT
This trial tests a drug called pasireotide as a maintenance therapy (given after standard treatment to keep cancer from coming back) for people with specific types of sarcoma. It's for patients whose tumors show high levels of certain proteins (SSTR) and who have stable or better disease after standard treatment.
Heidelberg, Baden-WurttembergAges 13–50 - NCT06464679RecruitingPhase 1
CD19 CAR NK cells for autoimmune diseases
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
ShanghaiAges 18–65 - NCT06469190RecruitingEarly Phase 1
CAR NK cells for treatment-resistant kidney disease
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
ShanghaiAges 18–70 - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75 - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT06516458Recruiting
Camera-based gait study for people with MS
This study uses a camera to measure how you walk, called gait quality, to better understand movement in multiple sclerosis. It may help develop a simple way to track walking changes over time.
Chicago, IllinoisAges 18–75 - NCT06519526RecruitingPhase 2
Study of two drugs for relapsed peripheral T-cell lymphoma
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
ShanghaiAges 18–70 - NCT06532643RecruitingEarly Phase 1
CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Hefei, AnhuiAges 14–70 - NCT06553053Recruiting
Acupuncture to prevent Crohn's disease relapse
This trial tests if acupuncture can help people with Crohn's disease stay in remission longer and avoid flare-ups. If you are in remission but have had frequent relapses, this study may be for you.
ShanghaiAges 16–75 - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT06582745RecruitingPhase 2
Trametinib for Langerhans cell histiocytosis (LCH)
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
Fort Worth, TexasAges 1–30 - NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06612944RecruitingPhase 2
Preventing relapse after stem cell transplant for high-risk MDS
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
ShanghaiAges 18–70 - NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT06660407RecruitingPhase 2
Grid radiation for advanced lung cancer after immunotherapy
This trial tests a special type of radiation called grid therapy for people with stage IV non-small cell lung cancer that has grown after immunotherapy or chemoimmunotherapy. It aims to see if this approach can help control tumors that are larger than 3 centimeters outside the brain.
Rochester, MinnesotaAges 18 years+ - NCT06681623Recruiting
Ublituximab in older adults with relapsing MS
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
Foxborough, MassachusettsAges 55–80 - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT06720324RecruitingPhase 1/Phase 2
CD7-targeted CAR-T therapy for relapsed blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Wuhan, HubeiAges 3–75 - NCT06755450RecruitingPhase 1
Study of AUR112 for advanced lymphoma or CLL
This trial tests a new oral medication called AUR112 for people with advanced lymphoma or CLL that has not responded to at least 2 prior treatments. The goal is to see if it is safe and how it works in the body.
Vadodara, GujaratAges 18–99 - NCT06785519RecruitingEarly Phase 1
CAR-T cell therapy for stubborn lupus kidney disease
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06824103RecruitingPhase 4
Study of ruxolitinib for chronic graft-versus-host disease in China
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hefei, AnhuiAges 12–100 - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,801 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.